Journal
NEUROLOGY
Volume 74, Issue 1, Pages S25-S30Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181c97e39
Keywords
-
Categories
Funding
- Teva Neuroscience
- National Institutes of Health [RO1 NS 37513]
- National Multiple Sclerosis Society
- NIH/NIAID
Ask authors/readers for more resources
Objective: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response. Methods: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques. Results: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented. Conclusions: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed. NEUROLOGY 2010; 74(Suppl 1):S25-S30
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available